Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.

Gorin MA, Soloway CT, Eldefrawy A, Soloway MS.

Urology. 2011 Mar;77(3):588-91. doi: 10.1016/j.urology.2010.10.039. Epub 2011 Jan 7.

PMID:
21215429
2.

Psychological aspects of active surveillance.

van den Bergh RC, Korfage IJ, Bangma CH.

Curr Opin Urol. 2012 May;22(3):237-42. doi: 10.1097/MOU.0b013e328351dcb1. Review.

PMID:
22357407
3.

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.

Dall'Era MA, Konety BR.

Nat Clin Pract Urol. 2008 May;5(5):277-83. doi: 10.1038/ncpuro1058. Epub 2008 Feb 19. Review.

PMID:
18285752
4.

[Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].

Leibovici D, Lindner A, Stay K, Zisman A.

Harefuah. 2006 Oct;145(10):763-7, 781, 780. Review. Hebrew.

PMID:
17111715
5.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6. Review.

PMID:
19286302
6.

[Active surveillance of prostatic cancer].

Vasarainen H, Ruutu M, Rannikko A.

Duodecim. 2011;127(6):593-9. Review. Finnish.

PMID:
21528523
7.

The economics of active surveillance for prostate cancer.

Dall'Era MA.

Curr Opin Urol. 2013 May;23(3):278-82. doi: 10.1097/MOU.0b013e32835f4b6b. Review.

PMID:
23449496
8.

Active surveillance for early-stage prostate cancer: review of the current literature.

Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR.

Cancer. 2008 Apr 15;112(8):1650-9. doi: 10.1002/cncr.23373. Review.

9.

The role of 5-alpha-reductase inhibitors in active surveillance.

Margel D, Fleshner N.

Curr Opin Urol. 2012 May;22(3):243-6. doi: 10.1097/MOU.0b013e328351dd57. Review.

PMID:
22472511
10.

Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Kakehi Y.

Asian J Androl. 2012 May;14(3):361-4. doi: 10.1038/aja.2011.151. Epub 2012 Apr 16. Review.

11.

Critical review: is watchful waiting a viable management option for older men with prostate cancer?

Bailey DE Jr, Wallace M.

Am J Mens Health. 2007 Mar;1(1):18-28. doi: 10.1177/1557988306294161. Review.

PMID:
19482780
12.
13.

Active surveillance versus radical treatment for favorable-risk localized prostate cancer.

Klotz L.

Curr Treat Options Oncol. 2006 Sep;7(5):355-62. Review.

PMID:
16904052
14.

Low-risk prostate cancer patient: active treatment.

Moul JW, Saad F.

Can J Urol. 2005 Jun;12 Suppl 2:25-7. Review.

PMID:
16018829
15.

Patient and disease factors affecting the choice and adherence to active surveillance.

Dall'Era MA.

Curr Opin Urol. 2015 May;25(3):272-6. doi: 10.1097/MOU.0000000000000154. Review.

PMID:
25692724
16.

Active surveillance for clinically localized prostate cancer--a systematic review.

Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P.

J Surg Oncol. 2014 Jun;109(8):830-5. doi: 10.1002/jso.23584. Epub 2014 Mar 7. Review.

PMID:
24610744
18.

[Active surveillance for prostate cancer].

Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H, Budäus L, Heinzer H, Huland H.

Urologe A. 2008 Mar;47(3):261-9. doi: 10.1007/s00120-008-1638-0. Review. German.

PMID:
18273597
19.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
20.

Active surveillance for prostate cancer: a review.

Klotz L.

Curr Urol Rep. 2010 May;11(3):165-71. doi: 10.1007/s11934-010-0110-z. Review.

PMID:
20425623

Supplemental Content

Support Center